Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P39900

UPID:
MMP12_HUMAN

ALTERNATIVE NAMES:
Macrophage elastase; Matrix metalloproteinase-12

ALTERNATIVE UPACC:
P39900; B2R9X8; B7ZLF6; Q2M1L9

BACKGROUND:
The enzyme Macrophage metalloelastase, known alternatively as Matrix metalloproteinase-12, is crucial for tissue remodeling and injury repair. It possesses a strong ability to degrade elastin, a key component in the extracellular matrix. The enzyme's substrate specificity includes a preference for leucine at the P1' position and hydrophobic or aromatic residues at the P1, with alanine being the preferred residue at P3.

THERAPEUTIC SIGNIFICANCE:
The exploration of Macrophage metalloelastase's function offers a promising avenue for therapeutic intervention. Given its significant role in tissue repair and remodeling, strategies aimed at modulating its activity could lead to breakthrough treatments for conditions characterized by excessive tissue damage or fibrosis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.